SecBot SecBot
DEFA14A ·Filed Apr 24, 2026

AXSM

Axsome Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001193125-26-177613
Proxy solicitation materials
Actionable Insight • Neutral

This is a routine annual proxy filing with no material developments. Monitor the company's next 10-Q or 10-K filing for financial performance updates and any changes in guidance.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$187.40
T+0 close · Apr 24, 2026 · via day close
Latest settled
+27.87%
T+60 · $239.62
Vs SPY
+23.09%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $187.40entry
  2. T+1 · 7mo ago −1.28%α −0.80% · $185.00
  3. T+5 · 7mo ago +19.37%α +18.97% · $223.70
  4. T+20 · 6mo ago +24.97%α +20.02% · $234.20
  5. T+60 · 4mo ago +27.87%α +23.09% · $239.62
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Axsome Therapeutics is holding its 2026 annual meeting for shareholders to vote on director elections, auditor ratification, and executive compensation. This is a routine annual governance filing with no material financial or strategic changes disclosed.

Key Financial Metrics

Vote
director election
Meeting
2026-06-05

Key Facts

  • Annual shareholder meeting scheduled for June 5, 2026
  • Voting on election of two directors: Mark Saad and Susan Mahony
  • Ratification of Deloitte & Touche LLP as independent auditor
  • Advisory vote on executive compensation
  • No material financial data, strategic changes, or unexpected events disclosed

Financial Impact

No financial impact from this filing

Risk Factors

  • None disclosed in this filing
  • Routine governance risk associated with any shareholder vote

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-177613
Document: 0001193125-26-177613-index-headers.html0001193125-26-177613
Document: 0001193125-26-177613-index.html0001193125-26-177613
Document: 0001193125-26-177613.txt0001193125-26-177613

Track record

26 reports on AXSM

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 2, 202614d ago 8-K Bullish 6/10 No price data
  2. Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
  3. Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
  4. Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
  5. Aug 10, 202614w ago 8-K Neutral 6/10 No price data
  6. Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
  7. Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
  8. Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
  9. Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
  10. Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 7h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026